Podcasts about siteman cancer center

In the third edition of a special podcast series, CancerNetwork® spoke with Daniel Morgensztern, MD; Mary Ellen Flanagan, NP; and Janelle Mann, PharmD, BCOP, about optimal strategies for incorporating different therapeutic agents into lung cancer care. As part of the latest discussion, the group highlighted the relevant efficacy data, administration protocols, and toxicity management considerations associated with TROP2-directed antibody-drug conjugates (ADCs) in patients with non–small cell lung cancer (NSCLC). Morgensztern is a professor of Medicine and the clinical director of Thoracic Oncology in the Division of Oncology at Washington University School of Medicine in St. Louis. Flanagan is a nurse practitioner in the Division of Thoracic Oncology at Washington University. Mann is a clinical oncology pharmacist at Siteman Cancer Center of Washington University School of Medicine and manager of Clinical Pharmacy Services at Barnes-Jewish Hospital. Morgensztern opened the discussion by highlighting the characteristics of prominent TROP2-targeting ADCs in NSCLC management, which included sacituzumab govitecan-hziy (Trodelvy), datopotamab deruxtecan-dlnk (Datroway), and sacituzumab tirumotecan (sac-TMT). Additionally, he reviewed data from clinical trials assessing these ADCs across different NSCLC populations, including the phase 3 EVOKE-01 trial (NCT05089734) showing a numerical overall survival (OS) improvement with sacituzumab govitecan vs docetaxel. Regarding the safety profiles of these ADCs, Flanagan described the unique toxicities associated with the agents' payloads as well as potential off-target effects. On top of myelosuppression, fatigue, and diarrhea, she stated that these therapies may cause more visceral organ toxicities like keratitis of the eye and interstitial lung disease. According to Flanagan, some prophylactic measures in the event of certain toxicities include frequent salt and baking soda mouth rinses as well as oral dexamethasone.  Mann then outlined the dosing variability considerations and supportive care measures surrounding the use of agents like sacituzumab govitecan. She emphasized continuously re-educating patients about expected toxicities and supportive care strategies as they undergo these infusion-based therapies to help avoid surprise instances of ocular toxicity, diarrhea, and other adverse effects. Reference Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study. J Clin Oncol. 2024;42(24):2860-2872. doi:10.1200/JCO.24.00733

KMOX Health Editor Fred Bodimer got reaction and some insight from Wash U and Siteman Cancer Center surgical urologist Dr. Sam Bhayani about the recent prostate cancer diagnosis of former President Joe Biden. Credit: © Ken Ruinard / staff / USA TODAY NETWORK via Imagn Images

Morgan had not turned 45 yet, so she hadn't received a screening colonoscopy for colorectal cancer. But when she noticed blood in her stool at age 41, she did exactly what she should have and sought medical evaluation. After months of missteps became years of dismissive care, she realized it was time for a second opinion at Siteman Cancer Center. With the help of WashU Medicine radiation oncologist Hyun Kim, MD, co-director of the Young-Onset Colorectal Cancer Program, Morgan was given a treatment plan that provided the care she needed. In this episode, we discuss her persistence and dedication to getting herself the best care for her young-onset colorectal cancer diagnosis.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/treatment/cancer-types/colorectal/young-onset-colorectal-cancer-program/ https://siteman.wustl.edu/treatment/cancer-types/colorectal/prevention-and-screening/  https://siteman.wustl.edu/doctor/kim-hyun/ https://getscreenednow.com/colon-cancer/ https://getscreenednow.com/insurance/  

In the second edition of a special podcast series, CancerNetwork® spoke with Daniel Morgensztern, MD; Mary Ellen Flanagan, NP; and Janelle Mann, PharmD, BCOP, about the best practices for incorporating recently approved bispecific antibodies into cancer care. This discussion focused on clinical trial results, administration protocols, and adverse effect (AE) management strategies related to the use of tarlatamab-dlle (Imdelltra) for patients with small cell lung cancer (SCLC). Morgensztern is a professor of Medicine and the clinical director of Thoracic Oncology in the Division of Oncology at Washington University School of Medicine in St. Louis. Flanagan is a nurse practitioner in the Division of Thoracic Oncology at Washington University. Mann is a clinical oncology pharmacist at Siteman Cancer Center of Washington University School of Medicine and manager of Clinical Pharmacy Services at Barnes-Jewish Hospital. The conversation opened with Morgensztern highlighting tarlatamab's mechanism of action as an agent that targets DLL3. He then reviewed prior efficacy data that the therapy demonstrated in the phase 1 DeLLphi-300 trial (NCT03319940) and the phase 2 DeLLphi-301 trial (NCT05060016). Of note, the FDA approved tarlatamab as the first available T-cell engager immunotherapy for patients with extensive-stage SCLC who have progressed on prior platinum-containing chemotherapy in May 2024 based on data from the DeLLphi-301 trial. Additionally, Flanagan detailed strategies for monitoring and mitigating the most common AEs associated with tarlatamab in this patient population, which include cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome. Mann then outlined considerations for properly dosing and administering the agent, highlighting factors that clinicians should keep in mind when continuing treatment in an inpatient or outpatient setting. The group also spoke about clinical decision-making related to patients who have brain metastases, which included processes for adjusting the dose of tarlatamab and sequencing the bispecific agent with radiotherapy. Reference FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. News release. FDA. May 16, 2024. Accessed March 14, 2025. https://tinyurl.com/48k34rw5

David A. Russler-Germain, MD, PhD, physician-scientist at Washington University School of Medicine and Siteman Cancer Center, discusses his path in oncology and the many advancements shaping lymphoma treatment today.

In the first edition of a special 3-part podcast series, CancerNetwork® spoke with Daniel Morgensztern, MD; Mary Ellen Flanagan, NP; and Janelle Mann, PharmD, BCOP, about best practices for implementing recently approved bispecific antibodies into cancer care. Their initial discussion focused on the clinical trial results, administration protocols, and toxicity management strategies related to the use of amivantamab-vmjw (Rybrevant) for patients with EGFR-mutated non–small cell lung cancer (NSCLC). Morgensztern is a professor of Medicine and clinical director of Thoracic Oncology in the Division of Oncology at Washington University School of Medicine in St. Louis. Flanagan is a nurse practitioner in the Division of Thoracic Oncology at Washington University in St. Louis. Mann is a clinical oncology pharmacist at Siteman Cancer Center of Washington University School of Medicine in St. Louis and manager of Clinical Pharmacy Services at Barnes-Jewish Hospital. Morgensztern began by giving an overview of amivantamab's mechanism of action and highlighting supporting data for the agent when administered alone or in combination with other agents.  The FDA initially approved amivantamab monotherapy for patients with EGFR exon 20 insertion–mutant NSCLC in May 2021 based on data from the phase 1 CHRYSALIS trial (NCT02609776). Furthermore, the agency approved amivantamab/chemotherapy as frontline treatment for patients with NSCLC harboring EGFR exon 20 insertion mutations in March 2024 based on data from the phase 3 PAPILLON trial (NCT04538664). Findings from the phase 3 MARIPOSA trial (NCT04487080) also supported the FDA approval of amivantamab plus lazertinib (Lazcluze) for those with EGFR-mutant NSCLC in August 2024. Additionally, Mann reviewed key dosing considerations as patients receive amivantamab via intravenous infusion. She detailed the use of premedication such as diphenhydramine (Benadryl) to supplement amivantamab while monitoring for toxicities during the initial infusion period, which may necessitate additional dosing adjustments. Flanagan added to the conversation surrounding infusion-related reactions by describing strategies for mitigating the risk of venous thromboembolism, cutaneous toxicities, and other adverse effects. References 1. RYBREVANTTM (amivantamab-vmjw) receives FDA approval as the first targeted treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. News release. The Janssen Pharmaceutical Companies of Johnson & Johnson. May 21, 2021. Accessed January 29, 2025. https://tinyurl.com/3d8wtu4m 2. FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications. News release. FDA. March 1, 2024. Accessed January 29, 2025. https://tinyurl.com/msw4u5yk 3. RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. News release. Johnson & Johnson. August 20, 2024. Accessed January 29, 2025. https://tinyurl.com/yxc8u8t4

KMOX Health Editor Fred Bodimer talked with Dr. Lindsay Peterson, a Washington University medical oncologist at Siteman Cancer Center regarding being 'cancer free'

Washington University researchers have found a way to greatly improve breast cancer risk predictions, by using artifical intelligence. KMOX Health Editor Fred Bodimer found out more about that when he talked with Dr. Joy Jiang, an associate professor of surgery at Wash U and and Siteman Cancer Center, and lead author of this new study.

Chaser takes time out from his battle with leukemia at Siteman Cancer Center to be our first legend. He gives a health update, tells stories of his youth hockey days in Porcupine Plains, Saskatchewan. He provides details on his rise to the NHL, and how it happened. And, you'll hear about the Blues-Wings battle in '93 that featured the goalie fight and much more with Detroit enforcer Bob Probert. Many thanks to Kelly for being our first legend on this podcast.

Kelly Chase joins the show to talk about his Leukemia diagnosis and the love and support he has received. Chaser also talks about how you can support Siteman Cancer Center and how he is raising money to help the fight against Cancer. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Kelly Chase joins the show to talk about his Leukemia diagnosis and the love and support he has received. Chaser also talks about how you can support Siteman Cancer Center and how he is raising money to help the fight against Cancer. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Washington University researchers find a vaccine that shows promise against aggressive breast cancer. KMOX Health Editor Fred Bodimer found out more about it from Wash U and Siteman Cancer Center surgical oncologist – Dr. William Gillanders.

It can be scary, difficult and complicated, but it doesn't always have to be. … Lung cancer is the No. 1 cause of cancer deaths — not just because of its aggressive nature, but because it's also frequently diagnosed late. But why? Hear from two survivors about their experiences and the importance of screening, which can catch lung cancer earlier, when it's more treatable.    “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/ https://siteman.wustl.edu/treatment/cancer-types/lung-cancer/ https://siteman.wustl.edu/treatment/cancer-types/lung-cancer/treatments/ https://siteman.wustl.edu/lung-cancer-screening/ https://siteman.wustl.edu/prevention/smoking-cessation-program/ https://siteman.wustl.edu/prevention/ydr/ https://www.smokingpackyears.com/ https://smokefree.gov/ https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/saved-by-the-scan

In today's episode, supported by Corcept Therapeutics, we had the pleasure of speaking with Premal Thaker, MD, MS, about the use of the selective glucocorticoid receptor modulator relacorilant (CORT125134) in patients with ovarian cancer. Dr Thaker is the David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology, as well as the director of Gynecologic Oncology Clinical Research and the interim chief of the Division of Gynecologic Oncology at the School of Medicine at the Washington University in St. Louis and the Siteman Cancer Center in Missouri. In our exclusive interview, Dr Thaker discussed the rationale for combining relacorilant with nab-paclitaxel (Abraxane) in patients with platinum-resistant ovarian cancer, striking phase 2 data (NCT03776812) with this combination in this population, and what the future has in store regarding the phase 3 ROSELLA trial (NCT05257408).

After minor blurred vision prompted Ellen to get an eye exam, she was surprised to learn she had a mass in the middle of her brain near the nerve connected to her left eye. A referral to Siteman quickly led to the diagnosis of a brain tumor. Fortunately, it was noncancerous and had a surgical solution. Washington University neurosurgeon Albert Kim, MD, PhD, director of The Brain Tumor Center at Siteman, explains minimally invasive surgery techniques and other new treatments that speed recovery for benign tumor patients like Ellen and others facing brain cancer.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/thisiscancer/ https://siteman.wustl.edu/ https://siteman.wustl.edu/neuro-oncology/ https://siteman.wustl.edu/treatment/cancer-types/brain-tumor-center/

When Byron was diagnosed with prostate cancer, he underwent surgery to have it removed. But when doctors noticed his PSA levels were still rising following the procedure, they offered him access to an open clinical trial. Byron shares his experiences from the 6-month trial along with his Washington University radiation oncologist Lannis Hall, MD. From upsides, to side effects, Byron and Dr. Hall use his story to illustrate the benefits of clinical trials, and how each trial's research furthers our understanding and potential cures for cancer.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/ https://siteman.wustl.edu/research/learn-about-clinical-trials/ https://siteman.wustl.edu/treatment/clinical-trials/ https://siteman.wustl.edu/treatment/clinical-trials/?path=gu-bladder-kidney-prostate-testicular-prostate https://siteman.wustl.edu/treatment/cancer-types/prostate/treatments/radiation-therapy-for-prostate-cancer/ https://siteman.wustl.edu/treatment/cancer-types/prostate/treatments/ https://siteman.wustl.edu/about/dei/

Former NHL player Kelly Chase is known as one of the toughest guys to wear a St. Louis Blues jersey, racking up more than 2,000 penalty minutes in his career. But when his Washington University oncologist Dr. Ramzi Abboud diagnosed him with acute myeloid leukemia in 2023, Chase learned he was facing an opponent different than anything he challenged on the ice – one needing more than brute force.    Listen as Chase and Dr. Abboud share the intense and taxing treatment plan needed to overcome Chase's rare cancer and what Chase learned about himself during his time at Siteman Cancer Center.     “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/thisiscancer/ https://siteman.wustl.edu/ https://siteman.wustl.edu/treatment/cancer-types/leukemia/ https://stlbluesalumni.com/Events/Puck-Cancer-Charity-Game  

This week, we're presenting stories from scientists who faced unusually difficult paths to science. We all know it's hard work to become a scientist. But for some folks, even getting to that point where you can pursue your science education can seem like an impossible dream. Part 1: When Evelyn Valdez-Ward discovers that she's undocumented, she fears her dreams of becoming a scientist are over.  Part 2: Samuel Achilefu's experiences growing up during the Nigerian Civil War inspire his passion for science.  Evelyn Valdez-Ward is an undocumented, Latina, scientist and PhD student at the University of California, Irvine. For her thesis, she studies the impact of California's drought on the ways that plants and their soil microbes (fungi and bacteria in the soil) communicate and interact with one another. In addition to doing research, she's extremely passionate about advocating for undocumented students in STEM. She recently published her story "I'm an undocumented scientist fighting for my Dream" in Science, and was invited to speak at the March for Science rally in DC to advocate for Dreamers in STEM. She has been awarded a UCI's Dynamic Womxn's Award for Outstanding Social Justice Activist, and the Svetlana Bersahdsky Graduate Student Award for her lobbying and advocacy efforts. She plans to continue lobbying and fighting for her undocumented community after graduating, and work in science policy, where she can continue to advocate for both science and minorities in STEM. Originally from Nigeria, Samuel Achilefu is the Michel M. Ter-Pogossian Professor of Radiology at Washington University School of Medicine. He also holds joint appointments as a Professor in Medicine, Biochemistry & Molecular Biophysics, and Biomedical Engineering and serves as the Chief of the Optical Radiology Laboratory (ORL), Director of the Molecular Imaging Center, Director of the Center for Multiple Myeloma Nanotherapy, and a co-leader of the Oncologic Imaging Program of the Siteman Cancer Center. His lab harnesses the power of light to develop methods for understanding, diagnosing and treating human diseases and is made up of biologists, chemists, engineers, medical scientists and physicists. He enjoys biking, playing tennis, and travelling. Samuel lives with his wife and they have two college-aged children. Learn more about your ad choices. Visit megaphone.fm/adchoices

In January of his senior year, Thomas was stretching and noticed a painless bump on the back of his hamstring. The 3-sport athlete thought nothing of it. But by the spring, the lump had grown to the size of a baseball. Thomas was immediately directed to Siteman kids where Washington University pediatric oncologist, Dr. Amy Armstrong, confirmed the mass was a sarcoma. Listen as Thomas, his mom Amelia, and Dr. Armstrong describe the long, intense treatment plan that delayed his plans for college football, and the mental grit it took to return to the sport he loved. Thomas also shares the advice he has for other young athletes.    After a diagnosis, every Siteman patient and their medical team develops a treatment plan, and every treatment plan becomes as unique as the patient it supports. Chuck learned how to tailor a treatment plan firsthand as he acted as a caregiver to his son, and again when he faced a cancer diagnosis himself. In this episode, Chuck shares his experience alongside Tate Rondot, Siteman's Manager of Support Services. Both are involved in Siteman's Patient and Family Advisory Council (PFAC), a group dedicated to helping every patient create the plan they need during their cancer care. They offer considerations and resources that personalize patients'  treatment from diagnosis to hospice and every stage in between.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/ https://siteman.wustl.edu/treatment/specialized-programs/sarcoma/ https://www.stlouischildrens.org/conditions-treatments/childhood-cancer-survivorship-program https://www.stlouischildrens.org/conditions-treatments/oncology-services/proton-beam-therapy https://siteman.wustl.edu/treatment/cancer-types/childhood-cancers/ https://siteman.wustl.edu/visiting/kids/ https://siteman.wustl.edu/doctor/armstong-amy/ https://siteman.wustl.edu/treatment/cancer-types/sarcoma/

Dr Tim Eberlein joins Tom Ackerman sharing news about an opening of a new facility in the St Louis area

The early symptoms were not clear. But after feeling “off” for a few days following a trip abroad, Candice took herself to the ER. Soon after, she was diagnosed with Stage 4 endometrial cancer. She was just 41. With the guidance and expertise of Washington University gynecologic oncologist, Dr. Premal Thaker, Candice welcomes each day, meeting it with unrelenting tenacity and spirit. Dr. Thaker shares about the rise of endometrial cancers in the U.S. (and globally) and discusses the red flag every postmenopausal woman needs to know. Listen to Candice's story and witness the powerful bond between patient and doctor with a common goal: fueling life with hope while facing cancer.    “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.    “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/ https://siteman.wustl.edu/treatment/cancer-types/uterus-endometrial/ https://siteman.wustl.edu/treatment/cancer-types/uterus-endometrial/symptoms-risks-and-diagnosis/ https://siteman.wustl.edu/treatment/cancer-types/uterus-endometrial/genetic-counseling-for-gynecologic-cancers/ https://siteman.wustl.edu/treatment/siteman-psychology-service/ https://getscreenednow.com/ https://siteman.wustl.edu/doctor/premal-thaker-md-ms/ https://siteman.wustl.edu/treatment/specialized-programs/gynecologic-oncology/

On this week's episode presented by Busey Bank, Josh gets the chance to sit with David Drier, the executive director of Pedal the Cause. Pedal provides critical funding for cancer research at Siteman Cancer Center and Siteman Kids at St. Louis Children's Hospital through their annual cycling challenge. Since 2010, over $45 million has been raised – with 100% of those funds directly supporting 223 cancer research projects. This is an organization that is hugely important to Josh and his team at Companion. They've participated since the beginning – in a handful of events throughout the year and feeding 3,000-4,000 riders breakfast the morning of the event each September.   David and Josh talk about his long-term involvement in Pedal in honor of his daughter Victoria who passed away from brain cancer in 2018, staying relevant as a maturing organization and the process of strategic planning for the next 15 years. Lessons applicable to all kinds of companies. Let's roll…   Please note: if you'd like to get involved with Pedal the Cause this September as a donor, rider or volunteer, please visit - https://pedalthecause.org/

In today's episode, Rebekah chats with Jen Cowan, writer of the blog And Hattie Makes Three! They discuss the joys and challenges of motherhood in the digital age and the exciting evolution of the blogging scene in St. Louis. Both share their experiences and insights, emphasizing the importance of striking a balance between technology use and spending quality time as a family, staying up-to-date with digital trends, while also prioritizing health and emotional well-being. We are so grateful to Siteman Cancer Center for sponsoring this episode. Listen to the stories of cancer survivors in season 3 of their "This is Cancer" podcast, available on all platforms. It will be sure to inform, uplift, and inspire you!Jen Cowan is the owner and founder of And Hattie Makes Three. It has always been her vision as a mom to help make long-lasting memories. She grew up in St. Louis and graduated from St. Louis University with a degree in Marketing. After graduating in '04, she spent her time around the St. Louis Metro area in a recruitment capacity for a few Fortune 500 Companies. In 2012, she was recruited away to her dream job, to manage the Internship Program for MasterCard. She had so much fun building a strong program and becoming an employer of choice at Universities. So now, instead of lunch meetings and quick flights out to colleges, she spends her time as a part-time Girl Scout Leader, PTO Parent, Cheer Mom and focusing on Miss H. Her family has a pretty action-packed social calendar so she created this blog to document life and what they do, where they go, new things they try and what they love. We hope you enjoyed this podcast episode! To learn more about Moms of the Lou you can go to stlouismom.com or follow us on Instagram and Facebook. You can listen to the podcast on Apple Podcast and Spotify. And don't forget to rate and review so more people can tune in! This episode was produced by the St. Louis Mom. It was recorded and edited by Half Coast Studios in St. Louis, Missouri. Music composed by Trina Harger.

In a conversation with CancerNetwork®, Brian A. Van Tine, MD, PhD, spoke about the FDA accelerated approval of afamitresgene autoleucel (afami-cel; Tecelra) for patients with metastatic or unresectable synovial sarcoma expressing MAGE-A4. He discussed the data from the phase 2 SPEARHEAD-1 trial (NCT04044768) supporting the agent's use in this patient population and highlighted how this approval might pave the way for other potential developments in the sarcoma landscape. Van Tine, a professor of medicine and pediatrics and a medical oncologist at Siteman Cancer Center of Washington University in St. Louis, detailed results from SPEARHEAD-1 leading to the FDA's approval of afami-cel. Based on these findings and the agent's potential availability as a one-time intravenous fusion, afami-cel may offer improvements in quality of life to patients with synovial sarcoma compared with standard treatment options such as chemotherapy. Topline data from cohort 1 of the SPEARHEAD-1 trial showed that treatment with afami-cel produced an objective response rate of 43% among 44 evaluable patients, which included a complete response rate of 4.5%. Additionally, the median duration of response was 6 months (95% CI, 4.6-not reached). Of patients with a response, durable responses lasting for 12 months or longer occurred in 39%.  In terms of other potential benefits following the accelerated approval of afami-cel, Van Tine said that the T-cell therapy may increase treatment access to specific subsets of patients. For those who are unable to relocate and live near certain treatment centers during their therapy, afami-cel may offer a more readily accessible alternative that can allow patients to undergo treatment at home. Van Tine also described how this accelerated approval may “open the gateway” for other advancements related to the use of afami-cel and similar agents in solid tumors.  “We're all working hard to get these therapies open at our institutions,” Van Tine said regarding the next steps for increasing access to afami-cel following the accelerated approval. “Knowing who [has] HLA-A*02–positive [disease], knowing who has synovial sarcoma, and being ready to trigger the screening for MAGE-A4 is in every patient's best interest. If you're one of the patients who have synovial sarcoma, you need to know your status [to determine] how we're going to integrate this into your care plan.” Reference Adaptimmune receives U.S. FDA accelerated approval of TECELRA® (afamitresgene autoleucel), the first approved engineered cell therapy for a solid tumor. News release. Adaptimmune Therapeutics. August 2, 2024. Accessed August 14, 2024. https://tinyurl.com/mw6k4hjh

After a diagnosis, every Siteman patient and their medical team develops a treatment plan, and every treatment plan becomes as unique as the patient it supports. Chuck learned how to tailor a treatment plan firsthand as he acted as a caregiver to his son, and again when he faced a cancer diagnosis himself. In this episode, Chuck shares his experience alongside Tate Rondot, Siteman's Manager of Support Services. Both are involved in Siteman's Patient and Family Advisory Council (PFAC), a group dedicated to helping every patient create the plan they need during their cancer care. They offer considerations and resources that personalize patients'  treatment from diagnosis to hospice and every stage in between.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/ https://siteman.wustl.edu/about/committees/patient-and-family-advisory-committee-pfac/ https://siteman.wustl.edu/visiting/patient-and-family-services/ https://siteman.wustl.edu/treatment/cancer-types/brain-tumor-center/ https://siteman.wustl.edu/treatment/cancer-types/prostate/ https://siteman.wustl.edu/treatment/siteman-psychology-service/ https://siteman.wustl.edu/treatment/survivorship/  

Yasmine Fehr joins Rebekah on this episode of Moms of the Lou as they discuss the significance of mental health in children, particularly as they return to school. They also talk about the significant mental health challenges faced by children and adolescents today, including the impact of technology and social media, and how to recognize signs of distress in early intervention. Both highlight the need for creating an open and non-judgmental environment to reduce stigma surrounding mental health issues.We are so grateful to Siteman Cancer Center for sponsoring this episode. Listen to the stories of cancer survivors in season 3 of their "This is Cancer" podcast, available on all platforms. It will be sure to inform, uplift, and inspire you!Yasmine Fehr is a psychiatric nurse practitioner who is board certified for the whole lifespan, but she specializes in pediatric and adolescent psychiatry. Check out Yasmine's blog post about Back to School Stress: How Can We Navigate This? Wondering about your child's mental health? Check out Yasmine's blog post about How Do I Know if My Child or Teen Needs Help with Mental Health. The Saint Louis Crisis Nursery is a great resource for keeping children safe and building stronger families.Originally from Memphis, TN, but St. Louis has been home since 2002 when she attended college at Washington University. She currently lives in Ellisville with her husband, Chris, son, Samuel, and their dog, Whitney B. She loves watching and streaming shows (favorites include “The Golden Girls,” “Seinfeld,” “Bob Hearts Abishola,” and “Only Murders in the Building), reading, walking, and spending time with friends and family. She is excited to continue to learn from other St. Louis moms as a new mother and is equally excited to share insights that can benefit children and adolescents.We hope you enjoyed this podcast episode! To learn more about Moms of the Lou you can go to stlouismom.com or follow us on Instagram and Facebook. You can listen to the podcast on Apple Podcast and Spotify. And don't forget to rate and review so more people can tune in! This episode was produced by the St. Louis Mom. It was recorded and edited by Half Coast Studios in St. Louis, Missouri. Music composed by Trina Harger.

Caring for a cancer patient can be a daunting undertaking, but also a meaningful act of love. In this episode, Courtney shares her journey as a caregiver for her husband, Charlie. She supported him as he battled a brain tumor for 18 of their 19 years of marriage. Patrick and Laura also share their experiences of caring for their fathers. Washington University clinical psychologist, Dr. Jennifer Romo, offers her expertise in helping caregivers. Through Siteman's support groups and individual sessions she helps them find balance in their lives, and validates their need to express and process the full spectrum of emotions.      “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/treatment/siteman-psychology-service/ https://siteman.wustl.edu/visiting/patient-and-family-services/ https://www.cancersupportcommunity.org/ https://annieshope.org/ https://www.cancer.org/cancer/caregivers.html https://www.cancer.gov/about-cancer/coping/caregiver-support https://siteman.wustl.edu/treatment/survivorship/

Cancer throws a lot of challenges - physical and mental - at patients. It can impact many areas of life, whether it's deciding if or how to tell loved ones, how to navigate relationship changes or even dealing with depression or anxiety. Licensed clinical psychologist Jessica Vanderlan, PhD, returns to the show to discuss these effects and how to boost mental and emotional well-being. The head of psychological counseling at Siteman Cancer Center, she emphasizes the need to prioritize mental health and offers insight and hope for patients and family members alike.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/treatment/siteman-psychology-service/ https://siteman.wustl.edu/treatment/survivorship/ https://siteman.wustl.edu/visiting/patient-and-family-services/ https://www.cancer.org/cancer/survivorship/coping.html https://www.cancersupportcommunity.org/

Dr. Sid Puram, clinical oncologist at Siteman Cancer Center and Tom Ackerman discuss prevention and treatment of head and neck cancers.

 Join Joe Pott and Cardinals manager Oliver Marmol for a comprehensive breakdown of the latest Cardinals game. Hear the exciting play-by-play as Alec Burleson hits a two-home run game, boosting the team to a 9-4 victory. Dive into a discussion about Miles Mikolas's recent pitching improvements and bullpen management strategies. Sponsored by the Siteman Cancer Center,

 oin Tom Ackerman for a jam-packed episode on Gray Bar Sports! First, dive into Negro Leagues history with Bob Kendrick. Then, Cardinals Manager Oliver Marmol discusses team strategy. Finally, rising racing star Spike Kohlbecker shares his journey. Don't miss the excitement! Sponsored by Siteman Cancer Center.

 Join Cardinals manager Oliver Marmol as he discusses the team's recent performances, player strategy, and upcoming challenges against the Phillies. Learn about the importance of player rotation for rest and performance optimization, Masyn Winn's team-first mindset, and insights into facing tough competition. Marmol also reflects on the bullpen's contributions and the impressive performance of Andre Pallante. Sponsored by Siteman Cancer Center.

Join Joe Pott as he interviews Cardinals manager Oliver Marmol, discussing the team's recent performance, player returns, and lineup strategies. Marmol reflects on the disappointing call that ended yesterday's game and emphasizes the team's need to capitalize on opportunities to secure wins. He shares insights into the emotional connection between players and fans, highlighted by Paul DeJong's warm reception from the crowd. Marmol previews Matthew Liberatore's start and the bullpen's efficiency and effectiveness. He also discusses the importance of Ryan Helsley's availability and lineup adjustments. 

Join us for an exciting charity game as the St. Louis Blues alumni face off against NHL celebrities, all in support of the fight against cancer. Bruce Affleck, from the Blues alumni group, discusses the event and the inspiring story of Kelly Chase, who battled and beat leukemia. The game will take place on Friday night, April 5, at the Centene Community Ice Center. Get your tickets on Ticketmaster starting March 1, and don't miss the chance to bid on autographed jerseys from current NHL stars. It's not just a game; it's a commitment to making a difference in the fight against cancer.

KMOX Health Editor Fred Bodimer talked with Dr. George Anasstas, Associate Professor of Medicine at Washington University and Leader of the Solid Tumor Treatment Program at Siteman Cancer Center to find out more about a new treatment approved by FDA for Melanoma

A moment of joy and a moment of deep change converge as patients ring the bell at the end of their treatment. This shift often calls for a different kind of care. Jessica Vanderlan, PhD, a clinical psychologist and manager of Siteman Psychology Service, and Rochelle Hobson, RN, MSN, CHPN, manager of Siteman's Survivorship Program, explain how their specialized training helps patients address the complexities of life after cancer treatment. And Jay, a Siteman Cancer Center patient, shares his first-hand experience navigating anxiety, change, and follow-up scans with help from the program's free mental health services.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/ https://siteman.wustl.edu/treatment/survivorship/ https://siteman.wustl.edu/treatment/siteman-psychology-service/ https://siteman.wustl.edu/visiting/patient-and-family-services/

In Part 2 of our Season 2 premiere we hear from Chelsea, who was diagnosed with HER2-positive breast cancer at age 37. She talks about why the one treatment she didn't want – five months of chemotherapy before undergoing her mastectomy – became her only option. Chelsea also reflects on how daily life as a mom of three became much more difficult. She reached her lowest point but pulled through with support from family and friends. Washington University breast surgeon Katherine Glover-Collins, MD, PhD, and Washington University plastic surgeon Terence Myckatyn, MD, join to explain why Chelsea's treatment plan required aggressive chemotherapy, and the strategy behind her reconstructive surgery.    “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/treatment/cancer-types/breast-cancer/ https://siteman.wustl.edu/prevention/8-ways/8-ways-to-prevent-breast-cancer/ https://siteman.wustl.edu/treatment/cancer-types/breast-cancer/patient-stories/ https://siteman.wustl.edu/treatment/siteman-psychology-service/ https://siteman.wustl.edu/treatment/survivorship/ https://siteman.wustl.edu/visiting/patient-and-family-services/ https://siteman.wustl.edu/visiting/patient-and-family-services/virtual-support-services/ https://siteman.wustl.edu/treatment/siteman-approach/chemotherapy/scalp-cooling/  

KMOX Health Editor Fred Bodimer talked about stomach cancer with Dr. Trang Nguyen, Washington University surgical oncologist at Siteman Cancer Center.

Aleta joins the show to share her battle with breast cancer. Her story begins with her diagnosis and what it was like to share the news with her family. She continues on to talk about going through treatment, only to have the cancer come back and eventually lead her to have a double mastectomy. Washington University radiologist Debbie Bennett, MD, chief of breast imaging, and Washington University clinical psychologist Jennie Romo shed light on the importance of mental and emotional support during those hard days, as well as the therapeutic resources Siteman offers.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/ https://siteman.wustl.edu/prevention/mammography/locations/mammography-van/  https://siteman.wustl.edu/visiting/patient-and-family-services/siteman-psychology-service/    

Siteman Cancer Center patient, Cheryl, shares the motivation that helped her endure three separate cancer diagnoses, a stem cell transplant and CAR T-cell therapy. Her Washington University medical oncologist, Amanda Cashen, MD, joins to explain the scientific advancements that saved Cheryl's life and allowed Cheryl to hold her first grandchild. Dr. Cashen also highlights new positive trends in treating all blood cancers.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/ https://siteman.wustl.edu/treatment/specialized-programs/stem-cell-transplant-and-cellular-therapies-center/ https://siteman.wustl.edu/treatment/cancer-types/lymphoma/

Diagnosed with cervical cancer at age 28, Mindy faced the emotional turmoil not just of surviving her diagnosis but also of how treatment could affect her plans for making a family. In this episode, she sits down with her Washington University Physicians, gynecologic oncologist Lindsay Kuroki, MD, MSCI and reproductive endocrinologist Kenan Omurtag, MD, to discuss the surgery that saved her life, as well as the physical and emotional complexities of fertility preservation and options available to women and men who face cancer.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/treatment/cancer-types/cervical/ https://siteman.wustl.edu/treatment/specialized-programs/gynecologic-oncology/ https://siteman.wustl.edu/facts-about-hpv-cervical-cancer/ https://siteman.wustl.edu/treatment/survivorship/infertility-fertility-preservation/ https://siteman.wustl.edu/visiting/payment-information/  

“If I can save one man's life, I'll have done my job.” In this episode, Kevin, prostate cancer survivor, talks about his crusade to save lives through awareness, with Washington University surgeon and urologist Arnold Bullock, MD, and Washington University medical oncologist Russell Pachynski, MD. They talk openly about a topic that many men find taboo to dispel myths and lay out facts about the No. 2 cause of cancer deaths among men.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/treatment/cancer-types/prostate/our-approach/ https://getscreenednow.com/prostate-cancer/ https://siteman.wustl.edu/for-your-health-understanding-prostate-cancer-screening-and-prevention/

In 2022, 11-year-old Addie traveled from central Illinois to Siteman Kids at St. Louis Children's Hospital with a brain tumor so rare that the type wasn't widely known anywhere. Addie and her mom, Ashley, are joined by Addie's child life specialist, Nikki, to discuss the surgery, proton therapy and emotional support that saved Addie's life – and the joy they found along the way.  Later in the episode, Washington University radiation oncologist Stephanie Perkins, MD, and Washington University hematologist-oncologist Margaret Shatara, MD, discuss childhood cancer, the latest advancements and the future of treating pediatric patients.  “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/treatment/cancer-types/childhood-cancers/ https://siteman.wustl.edu/visiting/kids/ https://siteman.wustl.edu/ https://siteman.wustl.edu/prevention/8-ways/8-ways-to-better-health-and-a-lower-risk-of-cancer-for-early-adults/

When patients describe their nurse, they often use words such as caregiver, teacher, counselor or friend. Three nurses at Siteman Cancer Center (Shannon, Pam and Julie) join the podcast to share their passion for taking care of cancer patients. Hear what inspired each of these nurses to get into the field – and the advice they share with patients.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/treatment/patient-experience/  https://siteman.wustl.edu/treatment/siteman-approach/ https://siteman.wustl.edu/visiting/

It wasn't Pam's first cancer diagnosis. In fact, because of a rare genetic disorder she has, Pam and her husband, Charlie, expected she would be diagnosed more than once. Together, they faced routine screenings and tests. But pancreatic cancer wasn't expected. An evening call in the fall of 2021 began Pam and Charlie's journey. While she received treatment, he supported her. Washington University medical oncologist Kian-Huat Lim, MD, PhD, and Washington University gastroenterologist Koushik Das, MD, explain how clinical trials, chemotherapy, surgery and new daily med ication make surviving pancreatic cancer possible.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/treatment/cancer-types/pancreatic/ https://siteman.wustl.edu/research/learn-about-clinical-trials/ https://siteman.wustl.edu/prevention/genetic-counseling/

Ron had referred patients for biopsies before, but the dentist didn't expect the lump in his own neck to be cancer. As one of a growing number of people diagnosed with HPV-related head and neck cancer, Ron shares about his treatment and why he advocates children being vaccinated against it. Though these cancers are on the rise, Washington University Otolaryngologist, Chief of Surgery at Siteman Cancer Center, Sidharth Puram, MD, PhD explains how HPV vaccines are key for preventing them entirely.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/treatment/cancer-types/head-and-neck/ https://siteman.wustl.edu/treatment/cancer-types/head-and-neck/hpv-head-and-neck-cancer/  https://siteman.wustl.edu/prevention/8-ways/8-ways-to-better-health-and-a-lower-risk-of-cancer-for-early-adults/

Do I need to have my breast removed? Will I lose them both? What about my nipples - will I get to keep them? How long before I can get reconstruction? Will I ever feel the same again? The unknowns women face after getting a breast cancer diagnosis are staggering. Our Season 2 premiere launches into the physical and emotional toll that breast cancer survivors endure. The experience and honesty they share took two whole episodes to convey. In Part 1, survivors Melanie and Tamara open up about their mastectomies, the challenges they were prepared for and the impact(s) they didn't expect.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.  For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/treatment/cancer-types/breast-cancer/ https://siteman.wustl.edu/prevention/8-ways/8-ways-to-prevent-breast-cancer/ https://siteman.wustl.edu/treatment/cancer-types/breast-cancer/patient-stories/ https://siteman.wustl.edu/treatment/siteman-psychology-service/ https://siteman.wustl.edu/treatment/survivorship/ https://siteman.wustl.edu/visiting/patient-and-family-services/ https://siteman.wustl.edu/visiting/patient-and-family-services/virtual-support-services/ https://siteman.wustl.edu/treatment/survivorship/body-image/ https://psychiatry.wustl.edu/patient-care-3/services-treatments/

"This is Cancer" returns for a second season - honest, compelling, and inspiring stories from cancer patients and the physicians who put forth miraculous efforts to treat them. This series is the perfect companion podcast - not only for people who've been touched by cancer, but for those of us who simply love the human experience. Brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, National Leaders in Cancer. "This is Cancer" premieres everywhere May 10th. “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO. For more information, visit siteman.wustl.edu

Resources, age, and mindset each play a key role in developing cancer treatment plans. Washington University radiation oncologist Lannis Hall, MD, MPH and former Siteman radiation therapist Larissa Bullock discuss how they take patients' unique challenges, like food insecurity, transportation, fertility, and psychological health, into account. Both explain why expert cancer care includes real support for tangible needs.    “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on Siteman Cancer Center, go to: https://siteman.wustl.edu/ https://siteman.wustl.edu/prevention/pecad/ https://siteman.wustl.edu/treatment/survivorship/ https://siteman.wustl.edu/visiting/patient-and-family-services/  

Why are two dissimilar cancers so commonly confused? Washington University radiation oncologist Maria Thomas, MD, PhD, and Washington University medical oncologist Neha Mehta-Shah, MD explain the differences and similarities of leukemia and lymphoma.   “This is Cancer” is brought to you by Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, and produced at Spot Content Studio in St. Louis, MO.   For more information on topics discussed in this episode, go to: https://siteman.wustl.edu/ https://siteman.wustl.edu/treatment/cancer-types/leukemia/ https://siteman.wustl.edu/treatment/cancer-types/lymphoma/